D C Baumgart

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. doi Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells
    Andreas Fischer
    Department of Medicine, Division of Gastroenterology and Hepatology, Humboldt University of Berlin, Berlin, Germany
    Am J Physiol Gastrointest Liver Physiol 304:G970-9. 2013
  2. doi Crohn's disease
    Daniel C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, Berlin, Germany
    Lancet 380:1590-605. 2012
  3. doi Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when?
    Daniel C Baumgart
    Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical Center Virchow Hospital, Medical School of Humboldt University of Berlin, Berlin, Germany
    Dig Dis 29:32-5. 2011
  4. ncbi CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis
    Daniel C Baumgart
    Charite Medical Center Virchow Hospital, Department of Medicine, Division of Gastroenterology and Hepatology Medical School of the Humboldt University of Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    Curr Opin Investig Drugs 11:571-6. 2010
  5. pmc Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease
    D C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical School of the Humboldt University of Berlin, D 13344 Berlin, Germany
    Clin Exp Immunol 157:423-36. 2009
  6. ncbi Inflammatory bowel disease: cause and immunobiology
    Daniel C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
    Lancet 369:1627-40. 2007
  7. ncbi Inflammatory bowel disease: clinical aspects and established and evolving therapies
    Daniel C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
    Lancet 369:1641-57. 2007
  8. ncbi [Mucosal dendritic cells: reaching out for the unknown (antigen)]
    D C Baumgart
    Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat zu Berlin, Germany
    Z Gastroenterol 40:375-7. 2002
  9. pmc The diagnosis and treatment of Crohn's disease and ulcerative colitis
    Daniel C Baumgart
    Medizinische Klinik mit Schwerpunkt Gastroenterologie und Hepatologie, Charite, Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Dtsch Arztebl Int 106:123-33. 2009
  10. doi Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease
    Daniel C Baumgart
    Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical School, Humboldt University of Berlin, Berlin, Germany
    Am J Gastroenterol 104:868-76. 2009

Detail Information

Publications45

  1. doi Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells
    Andreas Fischer
    Department of Medicine, Division of Gastroenterology and Hepatology, Humboldt University of Berlin, Berlin, Germany
    Am J Physiol Gastrointest Liver Physiol 304:G970-9. 2013
    ..Barrier protection might therefore constitute a novel mechanism how anti-TNF-α therapy contributes to epithelial restitution and tissue repair in inflammatory bowel diseases...
  2. doi Crohn's disease
    Daniel C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, Berlin, Germany
    Lancet 380:1590-605. 2012
    ....
  3. doi Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when?
    Daniel C Baumgart
    Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical Center Virchow Hospital, Medical School of Humboldt University of Berlin, Berlin, Germany
    Dig Dis 29:32-5. 2011
    ..Dysplasia can be graded by the Vienna or Riddell classification. Colectomy is recommended for patients with flat high-grade dysplasia confirmed by an expert gastrointestinal pathologist...
  4. ncbi CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis
    Daniel C Baumgart
    Charite Medical Center Virchow Hospital, Department of Medicine, Division of Gastroenterology and Hepatology Medical School of the Humboldt University of Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    Curr Opin Investig Drugs 11:571-6. 2010
    ....
  5. pmc Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease
    D C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical School of the Humboldt University of Berlin, D 13344 Berlin, Germany
    Clin Exp Immunol 157:423-36. 2009
    ..001 versus P < 0.01, respectively). Our data suggest an aberrant LPS response of mDC in IBD patients, resulting in an inflammatory phenotype and possibly intestinal homing in acute flares...
  6. ncbi Inflammatory bowel disease: cause and immunobiology
    Daniel C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
    Lancet 369:1627-40. 2007
    ..Implications for novel therapies, which are discussed in detail in the second paper in this Series, are covered briefly...
  7. ncbi Inflammatory bowel disease: clinical aspects and established and evolving therapies
    Daniel C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
    Lancet 369:1641-57. 2007
    ..Finally, we summarise the practical aspects of standard therapies including dosing, precautions, and side-effects...
  8. ncbi [Mucosal dendritic cells: reaching out for the unknown (antigen)]
    D C Baumgart
    Universitatsklinikum Charite, Campus Virchow Klinikum, Humboldt Universitat zu Berlin, Germany
    Z Gastroenterol 40:375-7. 2002
  9. pmc The diagnosis and treatment of Crohn's disease and ulcerative colitis
    Daniel C Baumgart
    Medizinische Klinik mit Schwerpunkt Gastroenterologie und Hepatologie, Charite, Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Dtsch Arztebl Int 106:123-33. 2009
    ..The purpose of this review article is to heighten awareness of these diseases among physicians whose primary clinical activities lie outside gastroenterology...
  10. doi Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease
    Daniel C Baumgart
    Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical School, Humboldt University of Berlin, Berlin, Germany
    Am J Gastroenterol 104:868-76. 2009
    ..Monoclonal antibodies to CD3 and CD4 T-cell receptors are evolving for Crohn's disease (CD) and ulcerative colitis. Their administration is often associated with a cytokine release syndrome (CRS)...
  11. ncbi Virchow's node
    Daniel C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre Virchow Hospital, Medical School of the Humboldt University of Berlin, Berlin, Germany
    Lancet 370:1568. 2007
  12. doi The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease
    Daniel C Baumgart
    Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical School, Humboldt University of Berlin, Berlin, Germany
    Digestion 76:196-202. 2007
    ..Therefore, the study of candidate genes involved in host pathogen interactions is of key interest...
  13. ncbi Personal digital assistants in health care: experienced clinicians in the palm of your hand?
    Daniel C Baumgart
    Department of Medicine, Charite Medical School, Virchow Hospital, Humboldt University of Berlin, D 13344 Berlin, Germany
    Lancet 366:1210-22. 2005
    ..A personal perspective and an introduction to medical PDA applications, software, guidelines, and programmes for health-care professionals is also provided...
  14. doi IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting
    Daniel C Baumgart
    Charite Medical School, Virchow Hospital, Humboldt University of Berlin, Germany
    Inflamm Bowel Dis 17:639-44. 2011
    ....
  15. ncbi Intestinal barrier function
    Daniel C Baumgart
    Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Department of Medicine, Division of Hepatology and Gastroenterology, Germany
    Curr Opin Clin Nutr Metab Care 5:685-94. 2002
    ..New therapeutic approaches including probiotics and peptides to restore disrupted barrier function are evolving...
  16. doi Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis
    Daniel C Baumgart
    Department of Medicine, Divisions of Gastroenterology and Hepatology, Charité Medical School of the Humboldt University of Berlin, Germany
    Inflamm Bowel Dis 16:620-9. 2010
    ..Visilizumab is a humanized IgG(2) monoclonal anti-CD3 antibody. We evaluated its safety and dose response in severe intravenous steroid-refractory ulcerative colitis (UC)...
  17. ncbi [Biologic therapy of inflammatory bowel disease]
    D C Baumgart
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Interdisziplinäres Stoffwechselzentrum, Universitatsklinikum Charite, Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin
    Z Gastroenterol 41:1017-32. 2003
    ..Based on the data discussed, it seems that biologicals will play an important role in managing inflammatory bowel disease in the near future...
  18. doi Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients
    Daniel C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Humboldt University of Berlin, Germany
    Inflamm Bowel Dis 17:2512-20. 2011
    ..Cutaneous lesions associated with its administration have not been prospectively studied in inflammatory bowel disease (IBD)...
  19. ncbi Current biological therapies for inflammatory bowel disease
    Daniel C Baumgart
    Charite Medical Center Virchow Hospital, Medical School of the Humboldt University, Department of Medicine, Division of Hepatology and Gastroenterology, D 13344 Berlin, Germany
    Curr Pharm Des 10:4127-47. 2004
    ..Based on the data discussed, it appears that biologics may play an increasing role in managing inflammatory bowel disease in the near future...
  20. doi Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis
    Saskia Thomas
    Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Berlin, Germany
    Am J Physiol Gastrointest Liver Physiol 301:G1083-92. 2011
    ....
  21. pmc Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells
    D C Baumgart
    Charité Medical Centre Virchow Hospital, Medical School of the Humboldt University, Department of Medicine, Division of Hepatology and Gastroenterology, D 13344 Berlin, Germany
    Gut 54:228-36. 2005
    ..Dendritic cells (DC) have been implicated in this process in various animal models, but data on human DC in IBD are very limited...
  22. pmc Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis
    D C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology Department of Surgery General Internal Medicine Outpatient Clinic, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
    Clin Exp Immunol 166:46-54. 2011
    ..We speculate that the impaired IFN-α secretion may relate to the hypothesized defect in innate immunity in IBD and could also impact upon the generation of regulatory T cells (T(reg) )...
  23. ncbi Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver
    Daniel C Baumgart
    Division of Hepatology and Gastroenterology, Charite Medical Center, Virchow Hospital, Medical School, Humboldt University of Berlin, D 13344 Berlin, Germany
    Gastrointest Endosc 61:473-5. 2005
  24. pmc What's new in inflammatory bowel disease in 2008?
    Daniel C Baumgart
    Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Augustenburger Platz 1, Berlin, Germany
    World J Gastroenterol 14:329-30. 2008
    ....
  25. pmc Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation
    S Thomas
    Department of Medicine, Division of Gastroenterology and Hepatology, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Berlin, Germany
    Clin Exp Immunol 156:78-87. 2009
    ....
  26. ncbi Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis
    C Buning
    Department of Gastroenterology, Hepatology and Endocrinology, Charite, Campus Mitte, Universitatsmedizin Berlin, Berlin, Germany
    Aliment Pharmacol Ther 26:1025-33. 2007
    ..A recent study reported that a non-synonymous single nucleotide polymorphism (rs11209026, p.Arg381Gln) located in the IL23R gene is a protective marker for inflammatory bowel disease...
  27. ncbi No association of the CARD8 (TUCAN) c.30T>A (p.C10X) variant with Crohn's disease: a study in 3 independent European cohorts
    Carsten Buning
    Department of Gastroenterology, Hepatology and Endocrinology, Charite, Campus Mitte, Universitatsmedizin Berlin, Germany
    Inflamm Bowel Dis 14:332-7. 2008
    ..The aim of this study was to analyze the frequency of p.C10X in 3 independent European (IBD) cohorts from Germany, Hungary, and the Netherlands...
  28. ncbi Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease
    D C Baumgart
    Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Department of Medicine, Division of Hepatology and Gastroenterology, Berlin, Germany
    Aliment Pharmacol Ther 17:1273-81. 2003
    ..Oral tacrolimus, approved for the prophylaxis of organ rejection in liver or kidney transplants, has been reported to be effective in anecdotal cases of refractory inflammatory bowel disease...
  29. ncbi Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms
    A U Dignass
    Department of Medicine, Division of Hepatology and Gastroenterology, Charité Medical School Virchow Hospital, Berlin, Germany
    Aliment Pharmacol Ther 20:9-17. 2004
    ..A better understanding of and enhancement of intestinal repair mechanisms may thus provide future approaches for the treatment of inflammatory bowel disease...
  30. pmc Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling
    Andreas Sturm
    Department of Hepatology and Gastroenterology, Campus Virchow Clinic, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, D 13353 Berlin, Germany
    Infect Immun 73:1452-65. 2005
    ....
  31. ncbi Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up
    Daniel C Baumgart
    Department of Medicine, Division of Hepatology and Gastroenterology, Charite Medical Center, Virchow Hospital, Medical School of the Humboldt University of Berlin, Germany
    Am J Gastroenterol 101:1048-56. 2006
    ..We and others have reported the use of tacrolimus in refractory inflammatory bowel disease (IBD). Little is known about its long-term efficacy and safety...
  32. doi Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer
    Uta Berndt
    Department of Medicine, Division of Gastroenterology and Hepatology, Charite Campus Virchow Klinikum, Universitatsmedizin Berlin, Berlin, Germany
    Cancer Res 68:880-8. 2008
    ..Thus, topological proteomic analysis may help to unravel the role of the adaptive immune system in colorectal cancer and aid the development of new antitumor immunotherapy approaches...
  33. pmc Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways
    A Grabig
    Charite Universitatsmedizin Berlin, Campus Virchow Clinic, Department of Hepatology and Gastroenterology, Augustenburger Platz 1, D 13353 Berlin, Germany
    Infect Immun 74:4075-82. 2006
    ..In conclusion, our data provide evidence that E. coli Nissle 1917 ameliorates experimental induced colitis in mice via TLR-2- and TLR-4-dependent pathways...
  34. ncbi [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?]
    B T Tanczos
    Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Universitatsklinikum Charite, Campus Virchow Klinikum, Medizinische Fakultat der Humboldt Universitat zu Berlin
    Z Gastroenterol 44:609-10. 2006
  35. ncbi CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway
    Andreas Sturm
    Department of Hepatology and Gastroenterology, Charite Universitatsmedizin Berlin, Campus Virchow, Augustenburger Platz 1, D 13353 Berlin, Germany
    Cytokine 29:42-8. 2005
    ..As intestinal epithelial cells have been recently shown to produce CXCL8, the aim of this study was to identify functional activities of CXCL8 on intestinal epithelial cells...
  36. ncbi Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism
    Daniel C Baumgart
    Department of Medicine, Division of Hepatology and Gastroenterology, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Germany
    Scand J Gastroenterol 40:958-64. 2005
    ..The aim of this study was to investigate whether 5-ASA also modulates intestinal epithelial wound repair in vitro...
  37. ncbi Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a
    Eckart Schott
    Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical School, Humboldt University of Berlin, Berlin, Germany
    World J Gastroenterol 13:3638-40. 2007
    ....
  38. doi Endocytoscopy for the detection of microstructural features in adult patients with celiac sprue: a prospective, blinded endocytoscopy-conventional histology correlation study
    Heiko Pohl
    Division of Gastroenterology and Hepatology, Department of Medicine, Charite Medical Center, Virchow Hospital, Medical School of Humboldt University of Berlin, Berlin, Germany
    Gastrointest Endosc 70:933-41. 2009
    ..Endocytoscopy (EC) is a novel technique that allows magnified live inspection of the intestinal mucosa...
  39. ncbi Viral gastroenteritis in adults
    Alexander J Eckardt
    Deutsche Klinik fur Diagnostik, Division of Gastroenterology and Hepatology, D 65191 Wiesbaden, Germany
    Recent Pat Antiinfect Drug Discov 6:54-63. 2011
    ..Special emphasis is put on current and future vaccines...
  40. ncbi Photo quiz. Obesity and daytime sleepiness. Prader-Willi syndrome
    Daniel C Baumgart
    Charite Medical School, Humboldt University of Berlin, Germany
    Am Fam Physician 68:151-2. 2003
  41. ncbi Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis
    Daniel C Baumgart
    Department of Medicine, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, D 13344 Berlin, Germany
    Inflamm Bowel Dis 10:421-4. 2004
    ..Complete non-scarring skin restitution without side effects was accomplished in both cases. Low dose oral tacrolimus provides a valuable alternative treatment option for IBD patients with refractory pyoderma gangrenosum...
  42. pmc Impact of pain on health-related quality of life in patients with inflammatory bowel disease
    Anja Schirbel
    Division of Gastroenterology and Hepatology, Department of Medicine, Charite Campus Virchow Clinic, Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    World J Gastroenterol 16:3168-77. 2010
    ..To evaluate intensity, localization and cofactors of pain in Crohn's disease and ulcerative colitis patients in connection with health-related quality of life (HRQOL) and disease activity...
  43. ncbi Lipoxins and resolvins in inflammatory bowel disease
    Karsten H Weylandt
    Department of Medicine, Division of Hepatology and Gastroenterology, Charité Medical School Virchow Hospital, Humboldt University of Berlin, Germany
    Inflamm Bowel Dis 13:797-9. 2007
    ..In this article we discuss the emerging knowledge on the effects of lipoxins and resolvins on various inflammatory pathways and why they are promising candidates for novel therapies of human inflammatory bowel disease...
  44. ncbi Recognition and appropriate management of dysplasia-associated lesions or masses in inflammatory bowel disease--experience does matter
    Daniel C Baumgart
    Gastrointest Endosc 66:530-2. 2007
  45. pmc Autoregulation of Th1-mediated inflammation by twist1
    Uwe Niesner
    German Rheumatism Research Center Berlin, 10117 Berlin, Germany
    J Exp Med 205:1889-901. 2008
    ....